Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Dezember 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
24. November 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.
18. November 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
17. November 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in...
12. November 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for...
06. November 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

All 84 sites for pivotal Phase 3 study in early AD are now fully activated, and the first group of patients has completed the 6-month treatment period.
27. Oktober 2025 08:00 ET | Quelle: Annovis Bio Inc.

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
15. Oktober 2025 17:15 ET | Quelle: Annovis Bio Inc.

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
10. Oktober 2025 08:31 ET | Quelle: Annovis Bio Inc.

Annovis Announces $6 Million Registered Direct Offering of Common Stock

MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
09. Oktober 2025 07:30 ET | Quelle: Annovis Bio Inc.

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

Nächste Seite